Core Insights - Cofo Medical has been dedicated to the home medical device industry since its establishment in 2007, aiming to provide convenient solutions for consumers and patients seeking high-quality and advanced home medical devices [2] - The company ranks as the second largest home medical device enterprise in China by sales revenue for 2024, according to Frost & Sullivan [2] - Cofo Medical has expanded its global presence, covering over 60 countries and regions across Asia, Africa, Europe, and America, while achieving full coverage on major e-commerce platforms in China [2] - In 2024, Cofo Medical's online sales reached approximately RMB 1.981 billion, placing it second among Chinese home medical device companies [2] - The company has a strong performance on various e-commerce platforms, with numerous product categories ranking first or within the top three in sales [2] Financial Performance - For the fiscal years ending December 31, 2022, 2023, and 2024, as well as the six months ending June 30, 2025, Cofo Medical reported revenues of approximately RMB 2.977 billion, RMB 2.854 billion, RMB 2.983 billion, and RMB 1.496 billion respectively [3][5] - The net profit for the same periods was approximately RMB 302 million, RMB 253 million, RMB 312 million, and RMB 167 million respectively [3][5] - The company operates 738 self-owned stores in China, with 689 being "Jianer Hearing" service centers, which provide professional hearing testing services and sell various quality hearing aids [3]

证券代码：301087 证券简称：可孚医疗 公告编号：2025-068 需要特别予以说明的是，本公告仅为境内投资者及时了解本次发行并上市的 相关信息而作出。本公告以及刊登于香港联交所网站的申请资料均不构成也不得 视作对任何个人或实体收购、购买或认购公司本次发行的境外上市外资股（Ｈ股） 的要约或要约邀请。 并刊发申请资料的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日向 香港联合交易所有限公司（以下简称"香港联交所"）递交了发行境外上市外资 股（Ｈ股）并在香港联交所主板挂牌上市（以下简称"本次发行并上市"）的申 请，并于同日在香港联交所网站刊登了本次发行并上市的申请资料。该申请资料 为公司按照香港证券及期货事务监察委员会（以下简称"香港证监会"）及香港 联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新和修订。 鉴于本次发行并上市的认购对象仅限于符合相关条件的境外投资者及依据 中国相关法律法规有权进行境外证券投资的境内合格投资者，公司将不会在境内 证券交易所的网 ...

Group 1 - Company Kefu Medical Technology Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange on August 29 [1]

Core Viewpoint - Tianxing Medical has submitted an application for listing on the Hong Kong Stock Exchange, aiming to capitalize on its position as a leading domestic sports medicine company in China [1][11]. Company Overview - Tianxing Medical focuses on comprehensive clinical solutions in sports medicine, covering various joints and providing treatment plans for soft tissue injuries [3][4]. - Established in July 2017, the company has developed a mature business system and competitive advantages, with a product portfolio that includes sports medicine implants, surgical equipment, and consumables [3][4]. - As of September 2024, the company has 47 approved sports medicine products, including 11 that are the first of their kind in China [3][4]. Financial Performance - The company has shown significant growth, with revenue increasing from 147 million yuan in 2022 to 327 million yuan in 2024, reflecting a strong compound annual growth rate [5][6]. - Net profit has also doubled during the same period, from 40.34 million yuan to 95.39 million yuan, indicating improved growth quality [5][6]. - The gross profit margin has remained high, at 68.7% in 2022, 70.3% in 2023, and 71.7% in 2024, further rising to 73.7% in the first five months of 2025 [6][5]. Market Position and Strategy - Tianxing Medical's products are used in over 3,000 hospitals across all 31 provinces in China, positioning the company favorably in the domestic market [4][5]. - The company aims to leverage the Hong Kong market for its capital needs, as it offers more flexible listing requirements compared to the A-share market [11][13]. - The shift to Hong Kong is part of a broader trend where companies seek to attract international capital and enhance their global presence [11][13]. Industry Context - The sports medicine consumables sector has been included in the national high-value medical consumables procurement list, leading to an average price drop of 74% for selected products, which is expected to benefit domestic manufacturers [8][10]. - The tightening of listing requirements in the A-share market has prompted companies like Tianxing Medical to explore alternative capital markets, highlighting a dual-track strategy of pursuing A-share listings while considering Hong Kong as a backup [14][11].

Core Viewpoint - Beijing Tianxing Medical Co., Ltd. is shifting its IPO strategy from the Sci-Tech Innovation Board to the Hong Kong Stock Exchange, reflecting broader industry trends and pressures in the domestic medical device market [2][10][12] Group 1: Company Overview - Tianxing Medical, established in 2017, focuses on comprehensive clinical solutions in sports medicine, covering various joint surgeries and extending into rehabilitation and prevention [3] - By 2024, Tianxing Medical has become the largest domestic sports medicine company in China, with 47 approved products, including 11 first-of-their-kind domestic products [4] Group 2: Financial Performance - From 2022 to 2024, the company's revenue grew from 147 million RMB to 327 million RMB, with a compound annual growth rate exceeding 40% [6] - Net profit increased from 40.34 million RMB in 2022 to 95.39 million RMB in 2024, indicating a doubling of profit scale [6] - The gross profit margin has remained high, with rates of 68.7%, 70.3%, and 71.7% from 2022 to 2024, further increasing to 73.7% in the first five months of 2025 [8] Group 3: Market Context - The sports medicine market in China was valued at approximately 6.09 billion RMB in 2023, projected to grow to 13.05 billion RMB by 2030, with a compound annual growth rate of about 11.5% [14] - The inclusion of high-value consumables in national procurement has led to an average price reduction of 74%, accelerating the domestic replacement process [14] Group 4: IPO Journey - Tianxing Medical's initial attempt to list on the Sci-Tech Innovation Board faced regulatory scrutiny, leading to a halt in the review process due to concerns over its "hard technology" attributes [11][12] - The decision to pursue a Hong Kong listing is part of a broader trend where companies seek more flexible capital markets that accommodate growth-oriented firms [13] Group 5: Strategic Implications - The shift to the Hong Kong market allows Tianxing Medical to tap into a more accommodating environment for innovative medical device companies, which is crucial for its international expansion strategy [16] - The company's rapid growth and market penetration reflect its strong position in the domestic sports medicine sector, but ongoing challenges from policy and competition remain [18]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Viewpoints - The company reported a revenue of 1.496 billion yuan for the first half of 2025, a year-on-year decrease of 4.03%, with a net profit attributable to shareholders of 167 million yuan, down 9.51% year-on-year [4][5] - The second quarter of 2025 saw a revenue of 758 million yuan, a year-on-year increase of 0.87%, while the net profit attributable to shareholders was 76 million yuan, down 9.30% year-on-year [5] - The overall gross margin improved to 52.80% in Q2 2025, indicating effective product structure optimization [5] Revenue and Profit Analysis - The rehabilitation aids segment is the largest business area, generating 563 million yuan in revenue for H1 2025, a decrease of 6.41% year-on-year, primarily due to the streamlining of inefficient SKUs [5] - The medical care product segment achieved revenue of 424 million yuan, up 9.67% year-on-year, mainly due to the acquisition of Huazhou [5] - Health monitoring products generated 271 million yuan in revenue, a year-on-year increase of 12.89%, driven by strong sales of thermometers and home testing strips [5] Online and Overseas Market Performance - Online channels contributed 974 million yuan in revenue for H1 2025, a year-on-year increase of 3%, accounting for 67.28% of total operating income [6] - The company has implemented differentiated operational strategies for various e-commerce platforms, enhancing customer retention and repurchase rates through a refined membership system [6] - The overseas business performed exceptionally well, with revenue exceeding 100 million yuan, a year-on-year growth of over 200% [6] Strategic Acquisitions - In January 2025, the company completed the acquisition of Shanghai Huazhou, a leading domestic pressure-sensitive adhesive manufacturer, which will enhance its product line and support overseas market expansion [8] - In June 2025, the company acquired a controlling stake in Ximan Medical Systems, a well-known medical instrument retailer in Hong Kong, facilitating entry into the Hong Kong market and resource integration [8] Financial Forecast - Revenue projections for 2025-2027 are 3.58 billion yuan, 4.33 billion yuan, and 5.24 billion yuan, with growth rates of 20.0%, 21.0%, and 20.8% respectively [9] - Net profit attributable to shareholders is expected to reach 414 million yuan, 504 million yuan, and 613 million yuan for the same period, with growth rates of 32.7%, 21.8%, and 21.7% respectively [9] - The estimated EPS for 2025-2027 is 1.98 yuan, 2.41 yuan, and 2.93 yuan, corresponding to P/E ratios of 20x, 17x, and 14x [9]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has shown a strong growth trajectory in its core product categories, with a year-on-year revenue increase of over 30% in key segments, indicating a promising long-term growth potential [2] - The company reported a total revenue of 1.496 billion yuan for the first half of 2025, a decrease of 4.03% year-on-year, with a net profit of 167 million yuan, down 9.51% year-on-year [2] - The company is accelerating its internationalization process and expanding its core product offerings, which is expected to drive future growth [2] Financial Performance Summary - For the first half of 2025, the company achieved a revenue of 1.496 billion yuan, with a net profit of 167 million yuan and a net cash flow from operating activities of 351 million yuan, reflecting a 14.46% increase year-on-year [2] - The sales gross margin for the first half of 2025 was 52.49%, an increase of 1.82 percentage points year-on-year, indicating improved profitability [2] - The company’s revenue projections for 2025-2027 are 3.33 billion, 3.91 billion, and 4.56 billion yuan respectively, with corresponding net profit estimates of 388 million, 484 million, and 589 million yuan, reflecting growth rates of 24.6% for 2025 and 2026 [4] Business Segment Performance - The medical care segment generated 424 million yuan in revenue, up 9.67% year-on-year, driven by new product launches and the consolidation of Shanghai Huazhou [2] - The health monitoring segment saw revenue of 271 million yuan, a year-on-year increase of 12.89%, with strong sales of key products such as blood glucose and uric acid testing devices [2] - The rehabilitation aids segment reported revenue of 563 million yuan, down 6.41% year-on-year, although the hearing aid segment experienced over 20% growth [2] Strategic Initiatives - The company is focusing on optimizing its product structure to enhance profitability and is investing in AI and brain-machine interface technologies to improve its competitive edge [2] - The company has made significant investments in research and development, with R&D expenditures reaching 46.95 million yuan in the first half of 2025, a 2.45% increase year-on-year [2] - The company has expanded its overseas market presence, achieving nearly 100 million yuan in overseas revenue in the first half of 2025, a growth of over 200% year-on-year [2]

Group 1: Company Insights - Kefu Medical is expected to achieve over 20% year-on-year revenue growth in hearing aid sales in the first half of 2025, with continued growth in existing store revenues and new store openings [1] - Kefu Medical's overseas business revenue has increased by over 200%, and the company has completed acquisitions of Shanghai Huazhou and Ximan Na, focusing future acquisitions on enhancing product lines or technology [1] - Zhonggang International has seen stable project execution with the Bolivia Mutong Steel Plant nearly completed and the Algeria Electric Furnace project passing inspection, achieving the fastest record overseas [2] - Zhonggang International's gross profit margin for engineering is projected to reach 14.22% in the first half of 2025, with both domestic and international margins improving [2] - Keli Equipment has made significant breakthroughs in light-absorbing coating technology, leading to adoption by Xiaomi Automotive, and is expected to see increased revenue and profitability as the electric vehicle market grows [3] - Tianfu Communication achieved a revenue of 2.456 billion yuan in the first half of 2025, a year-on-year increase of 57.84%, with net profit rising by 37.46% to 899 million yuan [4] Group 2: Market Trends and Challenges - The steel industry is facing challenges with a 3.0% year-on-year decline in crude steel production, although overall industry performance is better than expected [2] - Keli Equipment is addressing tariff impacts through trade terms design and local production in the U.S., ensuring stable overseas business expansion [3] - Tianfu Communication's gross margin has decreased due to changes in product structure, with a higher proportion of revenue coming from active products [4]

Group 1: Key Insights from Kefu Medical - Kefu Medical's hearing aid revenue is expected to grow over 20% year-on-year in the first half of 2025, with plans to enhance revenue from existing stores and new outlets in the second half [1] - The company has invested in Niu Lingke Medical to address congenital hearing loss, aiming for strategic synergy [1] - Overseas revenue has increased by over 200%, with successful acquisitions of Shanghai Huazhou and Ximan Na, focusing future mergers on enhancing product lines or technology [1] Group 2: Key Insights from China Steel International - China Steel International's projects are executing smoothly, with the Bolivia Mutong Steel Plant nearly completed and the Algeria Electric Furnace project passing inspection [2] - The company reported a year-on-year increase in accounts receivable and has strengthened its collection mechanisms [2] - The gross profit margin for engineering projects is expected to reach 14.22% in the first half of 2025, with both domestic and international margins improving [2] Group 3: Key Insights from Tianfu Communication - Tianfu Communication achieved a revenue of 2.456 billion yuan in the first half of 2025, a year-on-year increase of 57.84%, with a net profit of 899 million yuan, up 37.46% [3] - Growth in active products is driven by increased deliveries of high-speed active products, with a strong demand for these products [3] - The company is expanding its production capacity in Thailand, with the first phase already operational and the second phase in development [3] Group 4: Key Insights from Citic Securities Investment Fund - Citic Securities Investment Fund was established in 2013, managing a total asset scale of 67.55 billion yuan, ranking 76th among 210 [4] - The fund has 117 public funds under management, ranking 65th, and has 23 fund managers, ranking 59th [4] - The best-performing public fund in the past year is the Citic Securities North Exchange Selected Two-Year Open Mixed A, with a net value of 2.8 and a growth of 264.75% [4]

Group 1: Company Insights - Kefu Medical (301087) is expected to achieve over 20% year-on-year revenue growth in hearing aid sales in the first half of 2025, with plans to enhance revenue from existing stores and new outlets in the second half [1] - The company has invested in Newlink Medical to address congenital hearing loss, aiming for strategic synergy [1] - Overseas revenue has increased by over 200%, with completed acquisitions of Shanghai Huazhou and Ximaner, focusing future mergers on targets that can supplement product lines or enhance technical capabilities [1] - Kefu Medical has developed a comprehensive product matrix across five major areas and is increasing investment in e-commerce platforms, advancing smart projects in respiratory, blood pressure, blood glucose, and oxygen generation [1] - Key products include respiratory machines and hearing aids, with a focus on revenue contribution and strategic value; respiratory machine sales are rapidly growing, leading the category on Douyin's e-commerce platform [1] Group 2: Industry and Fund Management - Heyuan Bio leverages generative AI for innovative sequence design, utilizing deep learning frameworks such as Transformer and Diffusion for sequence scoring and generation [1] - Zhongjia Fund, established in 2013, has an asset management scale of 141.193 billion yuan, ranking 49th out of 210 in total public funds and 42nd out of 210 in non-monetary public funds [1] - The fund manages 135 public funds, ranking 60th out of 210, with 19 fund managers, ranking 72nd out of 210 [1] - The best-performing public fund product in the past year is Zhongjia Technology Innovation Mixed Fund A, with a latest unit net value of 1.68 and a growth of 128.28% over the past year [1] - The latest public fund product launched is Zhongjia CSI 300 Dividend Low Volatility Index A, which is an index-type stock fund, with a subscription period from August 18, 2025, to September 5, 2025 [1]